1.International research progress of risk factors, diagnosis and management in early chronic obstructive pulmonary disease.
Huiru LI ; Linqiong ZHOU ; Chunlei DUAN ; Weihong HAN ; Minghang WANG ; Suyun LI
Chinese Critical Care Medicine 2023;35(12):1340-1344
Chronic obstructive pulmonary disease (COPD) has a high global morbidity and mortality and a severe disease burden, yet progress in treatment and prevention has been slow in recent decades. Early COPD has few symptoms and is severely underdiagnosed and undertreated; it is crucial to search for effective clues of early COPD and provide management interventions. By reviewing the definition, risk factors, diagnosis and management interventions, this study explores the disease evolution of early-stage COPD, which can help clinical practice to develop more effective preventive and therapeutic strategies for stopping or slowing down the natural progression of the disease, improving the long-term prognosis, and reducing the disease burden.
Humans
;
Pulmonary Disease, Chronic Obstructive/drug therapy*
;
Prognosis
;
Risk Factors
2.The research progress of high altitude environment-associated chronic obstructive pulmonary disease and therapeutic drugs.
Xiang-Hai ZENG ; Ge-Le SUONAN ; Qin HUANG ; Yu LI ; Xiao-Jing ZHANG ; Wen-Bin LI ; Rong WANG
Acta Physiologica Sinica 2023;75(5):691-702
The plateau environment is characterized by low oxygen, low air pressure, low temperature, and strong ultraviolet rays, etc. Chronic obstructive pulmonary disease (COPD) is a preventable and treatable chronic lung disease. High altitude environment increases COPD prevalence, clinical manifestation and mortality. The therapeutic window of theophylline drugs for COPD is narrow, and the high altitude environment has an influence on the pharmacokinetics of the drugs. This review summarizes the differences in the prevalence, mortality, clinical manifestation and clinical symptoms of COPD in the plateau and plain, providing a basis for identifying the risk factors of COPD in the plateau areas. The effects of plateau hypoxic environment on the pharmacokinetics of COPD drugs were also discussed. It can provide a rationale for more effective prevention and treatment of COPD at high altitude.
Humans
;
Altitude
;
Pulmonary Disease, Chronic Obstructive/drug therapy*
;
Oxygen
;
Hypoxia
5.Analysis of acupoint selection of plaster therapy in treatment of stable chronic obstructive pulmonary disease based on data mining.
Qing CAO ; Qing MIAO ; Xing LIAO ; Chang-Zheng FAN ; Mao-Rong FAN ; Yi-Ling FAN ; Ma QIU-XIAO ; Ning WANG ; Ya-Ni HAO
China Journal of Chinese Materia Medica 2020;45(22):5356-5361
This article analyze acupoint selection and characteristics of plaster therapy for stable chronic obstructive pulmonary di-sease(COPD) by data mining. The CNKI, VIP, CBM, WanFang, PubMed, EMbase, Cochrane Library were retrieved for collecting clinical studies of plaster therapy for stable COPD. After literature screening, a total of 46 systematic reviews were included. Frequency statistics, cluster analysis, and Apriori correlation analysis were used to analyze the pattern and characteristics of plaster therapy for stable COPD. The result showed that the main acupoints for stable COPD were BL13, Dingchuan, CV22, BL23 and BL20. The acupoints used are mainly concentrated on the chest and back. The most frequently used meridian is the bladder meridian. Analysis of the acupoints yielded 27 correlation rules. And cluster analysis grouped the high frequency acupoints into 5 categories. The results of the study showed that the current choice of acupoints is rather concentrated. "Local acupuncture points" and "matching points with front and back" were the main acupoint selection rules. The choice of acupuncture points reflected the traditional Chinese medicine treatment principle of strengthening healthy Qi to eliminate pathogenic factor, treating both manifestation and root cause of disease, and preventing measure taken after the occurrence of disease.
Acupuncture Points
;
Acupuncture Therapy
;
Data Mining
;
Humans
;
Meridians
;
Pulmonary Disease, Chronic Obstructive/drug therapy*
7.Pharmacotherapy in Stable Chronic Obstructive Pulmonary Disease.
Journal of the Korean Medical Association 2006;49(4):333-341
The general approach to manage stable COPD is characterized by a stepwise increase in treatment, depending on the severity of the disease. None of the existing medications for COPD have been shown to modify the long-term decline in lung function that is the hallmark of the disease. Therefore, pharmacotherapy in COPD is used to decrease symptoms and /or complications. Bronchodilator medications are central to the symptomatic management of COPD. They are given on an as-needed basis or on a regular basis to prevent or reduce symptoms. The principal bronchodilator treatments are beta2-agonists, anticholinergics, theophylline, and a combination of these drugs. Regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting bronchodilators, but more expensive. The addition of regular treatment with inhaled steroids to bronchodilator treatment is appropriate for symptomatic COPD patients with an FEV1<50% predicted (Stage III: Severe COPD and Stage IV: Very Severe COPD) or repeated exacerbations (for example, more than 3 times during the last 3 years). Chronic treatment with systemic steroids should be avoided, if possible.
Bronchodilator Agents
;
Cholinergic Antagonists
;
Drug Therapy*
;
Humans
;
Lung
;
Pulmonary Disease, Chronic Obstructive*
;
Steroids
;
Theophylline
10.Clinical practice guideline for stable chronic obstructive pulmonary disease with traditional Chinese medicine (draft version for comments).
Chang-Zheng FAN ; Qing MIAO ; Mao-Rong FAN ; Xing LIAO ; Qiong ZHANG ; Yi-Ling FAN ; Ma QIU-XIAO ; Qing CAO ; Ning WANG ; Ya-Ni HAO
China Journal of Chinese Materia Medica 2020;45(22):5309-5322
By referring to the standards and procedures of WHQ Handbook for Guideline Development, under the guidance of relevant laws, regulations, and technical documents, in line with the principle of "evidence-based, consensus-based, experience-based", and based on the best available evidences, fully combined with expert experience and patient preferences, we summarized eight clinical questions in this paper: can traditional Chinese medicine(TCM) treatment improve the clinical symptoms and the degree of dyspnea in patients with stable chronic obstructive pulmonary disease(COPD) Can TCM treatment reduce the number of exacerbations in patients with stable COPD? Can TCM treatment improve the exercise tolerance of patients with stable COPD? Can TCM treatment improve the quality of life of patients with stable COPD? Can TCM treatment delay the decline of lung function in patients with stable COPD? Can TCM treatment improve anxiety and depression in patients with stable COPD? Does the point application therapy benefit patients with stable COPD? Can non-pharmacological treatment benefit patients with stable COPD? Based on these eight clinical problems, the cha-racteristics of TCM itself, and actual clinical situation, the recommendations of TCM to treat the stable COPD were formed in this guideline, with intention to provide advice and guidance to clinicians in the use of TCM to treat stable COPD, to relieve symptoms, improve exercise tolerance, improve health status, prevent disease progression, prevent and treat exacerbations, and improve clinical efficacy. Due to the influence of the user's region, nationality, race and other factors, the implementation of this guideline should be based on the actual situations.
Dyspnea
;
Humans
;
Medicine, Chinese Traditional
;
Pulmonary Disease, Chronic Obstructive/drug therapy*
;
Quality of Life
;
Treatment Outcome